Drug Discovery World

APRIL 4, 2023

Companies Evergreen Discovery and Orbit Discovery have entered into a collaboration to identify specific cell targeting peptides and advance the development of novel radiopharmaceuticals. The radiopharmaceuticals market is rapidly expanding with the development of a variety of targeting moieties.

In-Vitro 52

In-Vitro DNA Development Drugs 52

XTalks

DECEMBER 28, 2023

BillionToOne, a company specializing in molecular diagnostics, has partnered with Janssen Research & Development, LLC, a Johnson & Johnson division, to conduct the AZALEA Phase III clinical trial globally. Such precise detection is crucial for accurately pinpointing patients most susceptible to developing severe HDFN.

Trials 97

Trials Clinical Trials Clinical Trials Antibody 97

BioTech 365

SEPTEMBER 20, 2020

SEVILLE, Spain–(BUSINESS WIRE)–Universal Diagnostics (UDX), an in-vitro diagnostics company developing minimally-invasive, blood-based solutions for detecting cancer early, announced today that promising new data for its investigational advanced adenoma (precursor lesions of colorectal cancer) detection blood test and multi-cancer detection (..)

In-Vitro 52

In-Vitro DNA Development 52

pharmaphorum

FEBRUARY 19, 2021

Once someone is infected with HIV it stays with them for life thanks to the retrovirus’s ability to inject its DNA code into the host. The cash will also help develop two other preclinical drugs, EBT-104 for Herpes Simplex Virus and EBT-107 for hepatitis B. The post Could CRISPR cure HIV?

Gene Editing 104

Gene Editing In-Vivo DNA In-Vitro 104

XTalks

APRIL 6, 2022

The personalized ctDNA blood test uses the RaDaR™ assay, a liquid biopsy platform developed by the company Inivata. Cancerous cells and tumors release small fragments of DNA into the bloodstream called circulating tumour DNA (ctDNA). Photo source: Inivata. Around 85 percent of cases are non-small cell lung cancer (NSCLC).

DNA 105

DNA In-Vitro Doctors Doctor 105

Bioengineer

JANUARY 16, 2024

Analysis of circulating tumor (ct) DNA at the time of treatment discontinuation or progression showed that 49% of patients in the AURA3 trial lacked the T790M mutation. Analysis of circulating tumor (ct) DNA at the time of treatment discontinuation or progression showed that 49% of patients in the AURA3 trial lacked the T790M mutation.

Genome 119

Genome Genomics Protein In-Vitro 119

Drug Discovery World

OCTOBER 9, 2023

Join DDW for this exclusive free event, Scaling up in vitro transcription: Key results and considerations , which is supported by Thermo Fisher Scientific. In vitro transcription (IVT) can be a complicated reaction. The effect of several variables on the IVT reaction using different size DNA templates was assessed.

In-Vitro 52

In-Vitro Reagent DNA Production 52

Drug Discovery World

NOVEMBER 2, 2023

Join DDW for this exclusive free event, Scaling up in vitro transcription: Key results and considerations , which is supported by Thermo Fisher Scientific. In vitro transcription (IVT) can be a complicated reaction. The effect of several variables on the IVT reaction using different size DNA templates was assessed.

In-Vitro 52

In-Vitro Reagent DNA Production 52

Roots Analysis

AUGUST 15, 2023

Overview of Cell Free Systems Cell-free systems are ­in-vitro platforms which allow occurrence of biochemical reactions in the absence of living cells. It is worth mentioning that the first reconstituted system, Protein Synthesis Using Recombinant Elements (PURE) , was developed in 2001.

Protein 52

Protein In-Vitro Production Reagent 52

Drug Discovery World

JANUARY 23, 2023

This action sensitised GBM cells to radiotherapy both in vitro and in vivo (in mouse models). “Our research has revealed cladribine as a radiosensitiser for GBM treatment by drug repurposing, which can offer multiple advantages,” says Prof Youn. “As GBM is a WHO grade IV brain tumour with dismal prognosis.

FDA Approval 52

FDA Approval Drugs In-Vivo In-Vitro 52

Drug Discovery World

OCTOBER 2, 2023

Join DDW for this exclusive free event, Scaling up in vitro transcription: Key results and considerations , which is supported by Thermo Fisher Scientific. In vitro transcription (IVT) can be a complicated reaction. The effect of several variables on the IVT reaction using different size DNA templates was assessed.

In-Vitro 52

In-Vitro Reagent DNA Production 52

Drug Discovery World

OCTOBER 16, 2023

Join DDW for this exclusive free event, Scaling up in vitro transcription: Key results and considerations , which is supported by Thermo Fisher Scientific. In vitro transcription (IVT) can be a complicated reaction. The effect of several variables on the IVT reaction using different size DNA templates was assessed.

In-Vitro 52

In-Vitro Reagent DNA Production 52

Roots Analysis

OCTOBER 16, 2023

DNA cloning refers to the process of generating multiple copies of a particular DNA segment. DNA and Gene Cloning involves the isolation of a DNA sequence of any species ( often a gene ) and its insertion into a vector to enable growth without any alteration in the original DNA sequence.

DNA 40

DNA Gene Protein In-Vitro 40

Roots Analysis

JANUARY 14, 2024

With the increased interest and gradual shift of investment from small molecule drugs to biologics and the establishment of several biologics manufacturing companies / biologics CMOs, more than 250 biologic therapies and vaccines have been developed, globally. They are different from small molecules in terms of their size and complexity.

Contract Manufacturing 40

Contract Manufacturing Manufacturing Protein Bacteria 40

The Pharma Data

DECEMBER 14, 2020

”) platform to transform drug discovery and development, and identify patients who will benefit from its portfolio of targeted oncology therapeutics, announced today new scientific data that substantiates blood brain barrier permeability (BBB) for its drug candidate LP-184. . . DALLAS , Dec. Lantern’s A.I.

Drugs 52

Drugs Genome Genomics DNA 52

Pharma Mirror

APRIL 21, 2024

With the rapid development of biotechnology and molecular medicine, the introduction of mRNA as a vaccine or therapeutic agent enables the production of almost any desired functional protein/peptide within the human body.

In-Vitro 130

In-Vitro Drugs Genetic Disease RNA 130

The Pharma Data

MAY 18, 2021

MMR is a molecular mechanism that functions to correct certain errors that can spontaneously occur during DNA replication. This companion diagnostic (CDx) provides clinicians with a standardised testing option that uses a comprehensive panel of DNA mismatch repair (MMR) biomarkers tested by immunohistochemistry (IHC).

FDA Approval 40

FDA Approval DNA Protein In-Vitro 40

XTalks

NOVEMBER 7, 2022

Liquid biopsy tests in oncology involve isolating entities such as circulating tumor cells (CTC), circulating tumor DNA (ctDNA) and tumor-derived exosomes. These tumor-derived entities are used to derive genomic and proteomic data. The same webinar held a Q&A session with Dr. Bahassi and two other experts from Medpace, Dr. Lyon L.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

Drug Discovery World

MAY 16, 2023

Skills gap Bruce Levine, International Society for Cell & Gene Therapy (ISCT) Immediate Past President and Chair, Strategic Advisory Council, says a critical challenge that has become apparent for the CGT sector is the need for workforce development and training resources. What are the global innovations in cell and gene therapy?

Gene Therapy 52

Gene Therapy Gene Manufacturing Marketing 52

The Pharma Data

MARCH 22, 2022

In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. Financial details of the agreement were not disclosed. Pfizer expects supply to be available to support orders in April 2022, and supply will continue throughout 2022, pending regulatory authorization or approval and according to country needs.

In-Vitro 52

In-Vitro Contract Manufacturing Manufacturing Production 52

XTalks

SEPTEMBER 30, 2020

The researchers thought there may be similar mutations among COVID-19 patients, and that they could identify individuals at risk of developing severe disease as well as provide leads for new therapies, explained Casanova. The team sequenced DNA from 659 critically ill COVID-19 patients and 534 controls with mild or asymptomatic disease.

Antibody 135

Antibody Genetics Research In-Vitro 135

The Pharma Data

SEPTEMBER 1, 2020

Antigen test reliably and quickly triages people suspected of SARS-CoV-2, with results ready in 15 minutes, allowing informed treatment decisions. Antigen test accurately screens individuals with known exposure to infected SARS-CoV-2 patients, providing fast answers regarding their infection status. Food and Drug Administration (FDA).

In-Vitro 52

In-Vitro Antibody Medicine Clinical Trials 52

Pfizer

AUGUST 15, 2022

It was developed to be administered orally so that it can be prescribed early after infection, potentially helping patients avoid severe illness (which can lead to hospitalization and death). In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. FDA Emergency Use Authorization Statement.

Drugs 99

Drugs Vaccination Vaccine In-Vitro 99

Drug Discovery World

OCTOBER 23, 2023

Join DDW for this exclusive free event, Scaling up in vitro transcription: Key results and considerations , which is supported by Thermo Fisher Scientific. In vitro transcription (IVT) can be a complicated reaction. The effect of several variables on the IVT reaction using different size DNA templates was assessed.

Production 52

Production In-Vitro Reagent DNA 52

XTalks

AUGUST 12, 2020

The identification of T cells that essentially ‘hide’ the virus has significant implications for developing therapeutic strategies to improve the treatment and long-term management of HIV. This may help explain why HIV is adequately controlled, but not eradicated, with current treatments. The research study was published in Cell Reports.

RNA 52

RNA Protein DNA In-Vivo 52

Pfizer

JANUARY 27, 2023

It was developed to be administered orally so that it can be prescribed early after infection, potentially helping patients avoid severe illness (which can lead to hospitalization and death). In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions.

Marketing 75

Marketing Production Drugs Licensing 75

Drug Discovery World

JANUARY 12, 2023

Oksana Sirenko looks at the advantages and limitations of using organoids from human cell sources in drug development and drug screening. . The genome is the blueprint for life, consisting of genes made up of thousands of pairs of DNA bases. What are organoids? .

Gene Editing 98

Gene Editing Gene Drugs In-Vivo 98

Drug Discovery World

MARCH 14, 2023

The success of messenger RNA (mRNA) vaccines in combatting the global SARS-CoV-2 crisis brings a new era of vaccine development. RNase inhibitor, inorganic pyrophosphatase), nucleoside triphosphates (NTPs), and a DNA template, to make each mRNA. Figure 2: TheraPure GMP products for mRNA production 2.

Production 52

Production RNA DNA Manufacturing 52

Pharmaceutical Technology

NOVEMBER 22, 2022

Vaccines are our number one weapon in the fight against infectious diseases, but their development has historically involved a long and complex process taking up to a decade. Before COVID-19, Merck held the record for the fastest modern vaccine ever developed. Single- and multi-nation funding opportunities flooded in.

Manufacturing 130

Manufacturing Vaccination Vaccine RNA 130

Roots Analysis

MARCH 16, 2023

Messenger ribonucleic acid (mRNA) is a single-stranded molecule that is complementary to a gene’s DNA. It is important in the process of protein synthesis because mRNA is responsible for transferring genetic information from DNA to ribosomes, which then decodes the genetic information into a protein.

Vaccination 52

Vaccination Vaccine DNA Protein 52

Drug Discovery World

JANUARY 17, 2024

With oncology accounting for a third of pharma’s product pipeline, significant challenges include fierce competition, high research and development costs over, 10-15 years for clinical development, and pressures to rapidly meet the demand for new treatments 2-4.

Medicine 59

Medicine DNA Genome Genomics 59

Drug Discovery World

APRIL 11, 2024

On the final day of AACR, the plenary session of the Annual Meeting put artificial intelligence at the forefront and featured a stellar lineup of AI and data science experts who discussed AI and topics such as imaging, precision medicine, and drug development. And thanks to the city of San Diego for its hospitality.”

HR 52

HR Antibody In-Vitro DNA 52

Drug Discovery World

FEBRUARY 28, 2023

With only 10% of these conditions indicated for an approved therapy, there is a sizable opportunity for scientists and companies to develop treatments for patients with no other options to turn to. Approximately 7,000 rare and ultra-rare diseases have been described, and yet, 90% have no approved therapeutic options 1.

Genetics 52

Genetics Genetic Analysis Vaccination Vaccine 52

XTalks

MAY 12, 2022

On Tuesday, the Aptima® CMV Quant Assay developed by Hologic Inc. This diagnostic assay works on the principle of in vitro nucleic acid amplification using real-time transcription-mediated amplification (TMA) technology. Cytomegalovirus (CMV) Infection in Transplant Recipients. percent increase compared to 2020.

In-Vitro 52

In-Vitro DNA Development Genome 52

The Pharma Data

SEPTEMBER 28, 2021

About the three new Roche tests for Influenza A/B, RSV; ADV, hMPV, EV/RV; and Parainfluenza 1-4 These tests utilise a real-time PCR macromolecule amplification method to detect specific DNA sequences obtained after extraction or following reverse transcription of RNA.

Marketing 52

Marketing In-Vitro DNA Bacteria 52

Pfizer

DECEMBER 13, 2022

It was developed to be administered orally so that it can be prescribed early after infection, potentially helping patients avoid severe illness (which can lead to hospitalization and death). In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. The additional 3.7

Drugs 110

Drugs Licensing Licensing Production 110

The Pharma Data

AUGUST 27, 2020

Cancer is a disease of the genome, driven by genetic mutations within a tumour’s DNA. Roche’s Executive Vice President, Chief Medical Officer, Head of Global Product Development and Co-Founder of Foundation Medicine Inc. The results are delivered in an integrated report that identifies alterations matched to FDA-approved therapies.

FDA Approval 52

FDA Approval Genome Genomics Gene 52